Bifidobacterium Infantis for Ibs Relief

Research suggests that Bifidobacterium infantis 35624 may help reduce certain IBS symptoms — particularly abdominal pain, bloating, and bowel dysfunction — in adults with the condition, based on findings from randomized controlled trials and a 2011 review of functional gastrointestinal disorder treatments that identified this specific strain as producing statistically significant reductions in bloating. However, the evidence is notably mixed: a 2006 RCT found that only one specific dose level outperformed placebo while others did not, and a 2017 RCT found no meaningful benefit over placebo in a general population of adults with milder, non-clinically-diagnosed symptoms, with researchers attributing the null finding to a strong placebo response and the less severe symptom burden of that study group. A 2016 systematic review also found preliminary support for Bifidobacterium strains in pediatric IBS, though that evidence base remains limited and the findings are not specific to the 35624 strain. Taken together, the available research indicates that B. infantis 35624 shows the most consistent benefit in clinically diagnosed IBS populations, but important questions remain about dosing, population selection, and the overall strength of the evidence, and more rigorous trials are needed before firm conclusions can be drawn.